ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

2:15PM-2:30PM: Abstract Number: 0479

A Novel Semi-automated Classifier of Radiographic Hip Osteoarthritis on DXA Scans Is Strongly Predictive of Pain, Clinical Diagnosis and Joint Replacement: Findings from 40,000 Participants in UK Biobank

Abstracts: Osteoarthritis – Clinical (0478–0483)

2:15PM-2:30PM: Abstract Number: 0489

CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases

Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

2:15PM-2:30PM: Abstract Number: 0485

The Impact of COVID-19 on Rheumatology Trainee Health and Wellbeing: Results from the COVID-19 Global Rheumatology Alliance Trainee Survey

Abstracts: Professional Education (0484–0487)

2:30PM-2:45PM: Abstract Number: 0486

A Practical Approach to Competency-based Evaluations and Milestone Mapping for Adult Rheumatology Fellowship Programs

Abstracts: Professional Education (0484–0487)

2:30PM-2:45PM: Abstract Number: 0490

Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways

Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

2:30PM-2:45PM: Abstract Number: 0480

Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis

Abstracts: Osteoarthritis – Clinical (0478–0483)

2:45PM-3:00PM: Abstract Number: 0487

A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors

Abstracts: Professional Education (0484–0487)

2:45PM-3:00PM: Abstract Number: 0491

Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study

Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

2:45PM-3:00PM: Abstract Number: 0481

The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study

Abstracts: Osteoarthritis – Clinical (0478–0483)

3:00PM-3:15PM: Abstract Number: 0482

Metformin Use Reduces the Risk of Developing Osteoarthritis: A Propensity Score Matching Study

Abstracts: Osteoarthritis – Clinical (0478–0483)

3:15PM-3:30PM: Abstract Number: 0483

Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs

Abstracts: Osteoarthritis – Clinical (0478–0483)

3:30PM-3:45PM: Abstract Number: 0502

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)

3:30PM-3:45PM: Abstract Number: 0492

Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus

Abstracts: Healthcare Disparities in Rheumatology (0492–0495)

3:30PM-3:45PM: Abstract Number: 0496

Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)

Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)

3:45PM-4:00PM: Abstract Number: 0503

18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].